Note: Galt Pharmaceuticals's revenues are gauged from an analysis of company filings.
Galt Pharmaceuticals's Income Statement (based on Industry Averages)
Galt Pharmaceuticals P&L
$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit
Trademark Applications
Trademark applications show the products and services that Galt Pharmaceuticals is developing and marketing.
Galt Pharmaceuticals doesn't have any recent trademark applications, indicating Galt Pharmaceuticals is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
CLINORIL Analgesic, antipyretic and anti-inflammatory agent
09/22/2020
MIDRIN Pharmaceutical Preparation for Treatment of Vascular and Tension Headaches
09/17/2020
MECLOMEN Anti-inflammatory preparations
08/11/2020
See all trademarks and details in the Full Report.
Market Share of Galt Pharmaceuticals's Largest Competitors
A competitive analysis shows these companies are in the same general field as Galt Pharmaceuticals, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Galt Pharmaceuticals.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Galt Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.